Verastem, Inc.
Close on Oct 19, 2026
- Market cap
- $863.00M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $40.10M | $-0.35 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 4, 2026 | Before market open | $17.50M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $11.20M | $-1.35 | $-0.54 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 2, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 8, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 28, 2022 | Before market open | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Aug 10, 2020 | Before market open | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | Apr 27, 2020 | Before market open | – | – | – |
| Q4 FY2019 Ended Dec 31, 2019 | Feb 28, 2020 | Before market open | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Oct 29, 2019 | After market close | – | – | – |
Press releases
Announcements Verastem filed with the SEC
Verastem Oncology Announces Planned Chief Executive
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
VS-7375 Demonstrates Robust Anti-Tumor Activity
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update October 14, 2026
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
C O R P O R A T E P R E S E N T A T I O N
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Verastem Oncology Reports Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update Call June 23, 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verastem Oncology Announces Positive Updated
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
C O R P O R A T E P R E S E N T A T I O N
Regulation FD disclosure · EX-99.1 to Form 8-K
C O R P O R A T E P R E S E N T A T I O N
Regulation FD disclosure · EX-99.1 to Form 8-K
Verastem Oncology Provides Preliminary Fourth
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verastem Oncology Announces Strategic Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Item 14. Other Expenses of Issuance and
Other events · EX-99.1 to Form 8-K
Verastem Oncology Reports Third Quarter 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | November 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verastem Oncology Announces Updated Data from
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | September 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verastem Oncology R&D Investor Event ASCO 2025 June 2, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Verastem Oncology Announces Updated Data from
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verastem Oncology Announces Positive Updated
Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
FDA Approves the AVMAPKI™ FAKZYNJA™
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verastem Oncology Announces $75 million Private
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | March 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
of avutometinib and defactinib in Low-Grade Serous Ovarian Cancer, the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc. (GenFleet), including the timing of the IND for VS-7375 and the initiation of a Phase 1/2a
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Verastem Oncology Announces Debt Refinancing
Material agreement · Agreement terminated · Results of operations · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Verastem Oncology Presents Positive Updated
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Item 14. Other Expenses of Issuance and
Other events · EX-99.1 to Form 8-K
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers June 2024 Corporate Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
Verastem Oncology Announces the Initiation of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers May 2024 Corporate Presentation
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Verastem Oncology Announces Positive Initial
Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
Verastem Oncology Outlines Key 2024 Strategic Priorities
Regulation FD disclosure · EX-99.1 to Form 8-K
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5 th Annual RAS-Targeted Drug Development Summit
Regulation FD disclosure · EX-99.1 to Form 8-K